Introduction {#s1}
============

Varenicline is an α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist (Rollema et al., [@B45]) that is more efficacious than nicotine replacement therapies or bupropion for smoking cessation (Gonzales et al., [@B20]) but still only results in smoking cessation rates of 25--30% 6 months after treatment (Tonstad et al., [@B51]). Thus, while varenicline is the single best agent currently available, new medications are needed for smoking cessation treatment. Apart from its action at nAChR, little is known about the mechanism of action of this drug. It is critical to understand the mechanism of action of varenicline so that more effective smoking cessation drugs can be developed.

Increasing evidence implicates glutamate in the pathophysiology of addiction (Kalivas et al., [@B26]), including nicotine addiction (Markou, [@B33]). Preclinical research in animal models of nicotine-dependence indicates that reducing glutamatergic transmission through pharmacological manipulations decreases the rewarding effect of nicotine (Paterson et al., [@B40]; Paterson and Markou, [@B39]). Furthermore, pre-clinical animal research indicates varenicline may act on glutamate levels by increasing glutamic acid decarboxylase expression in prefrontal cortex (Maloku et al., [@B32]). In humans, measures of central glutamate levels can be obtained using proton magnetic resonance spectroscopy (^1^H-MRS). Specifically, prior MRS studies suggest a role for ACC glutamate levels in the modulation of addiction behaviors. A recent MRS study in alcohol-dependent subjects (Umhau et al., [@B53]) found a reduction of glutamate levels in the anterior cingulate cortex (ACC) following a 4-week treatment with acamprosate, a drug approved for the maintenance of alcohol dependence. Similarly, a positive correlation was found between alcohol craving and rostral ACC Glx levels in alcohol-dependent patients immediately after detoxification (Bauer et al., [@B5]). Changes in ACC glutamate after administration of varenicline might suggest a mechanism by which the drug decreases addiction. However, there have been no prior MRS studies of pharmacologically supported smoking cessation.

A number of functional magnetic resonance imaging (fMRI) studies have been conducted investigating the effects of varenicline; they suggest that the drug diminishes physiological responses that lead to relapse such as smoking cue reactivity (Franklin et al., [@B17]) and the mental disturbances experienced during withdrawal (Loughead et al., [@B31]; Sutherland et al., [@B49]). One of the long term benefits of treatment for smoking cessation is the ability to regain control over smoking cues. Several imaging studies indicate that cognitive control, or the ability to shift the processing of perceptual information toward relevant goals, is impaired in addiction (Harding et al., [@B22]). Azizian et al. ([@B4]) showed that nicotine modulates the blood oxygen level dependent (BOLD) response in regions of the cognitive control network (CCN) (Niendam et al., [@B38]). On the other hand, investigation of the effects of nicotine on functional connectivity (FC), a measure of temporal coherence of spontaneous neural activity between brain regions, reported changes in FC with regions of the default mode network (DMN) (Raichle and Snyder, [@B43]), a neural network associated with rest and independent of task or external stimuli (Mason et al., [@B35]). Since acute administration of nicotine changes the FC between regions of the CCN and DMN (Cole et al., [@B10]), we were interested in assessing the effect of varenicline on BOLD response and FC between networks.

The aim of this study was to investigate the effect of a 12 week smoking cessation therapy with varenicline on glutamate levels and cognitive control function. We acquired single-voxel ^1^H-MRS measurements in the dorsal ACC (dACC) to obtain glutamate measurements. To activate the CCN, we chose a Stroop color-naming task, which has been shown to produce robust activation in the dACC during high-conflict trials (Azizian et al., [@B4]). To investigate CCN FC during the Stroop, we conducted a psychophysiological interaction analysis with the dACC as seed region. On the basis of the existing literature (Markou, [@B33]; Kalivas et al., [@B26]; Azizian et al., [@B4]; Cole et al., [@B10]), we hypothesized that dACC glutamate + glutamine (Glx) levels would decrease and dACC BOLD signal and connectivity would be altered after treatment with varenicline. Finally, to explore patterns that would predict adherence to smoking cessation therapy, we contrasted glutamate levels and BOLD response between those who completed the study and those who dropped out after completing the baseline scanning session.

Materials and methods {#s2}
=====================

Participants
------------

We recruited 22 adult participants (age 19--65) who smoked at least 10 cigarettes per day (cpd) and desired smoking cessation treatment via advertisements in flyers and the University of Alabama at Birmingham (UAB) newspaper. Exclusion criteria were major medical conditions, substance abuse other than nicotine within 6 months prior to enrollment, previous serious head injury, a neurologic disorder, loss of consciousness for more than 2 min, and pregnancy. The UAB Institutional Review Board approved the study, and all participants provided written informed consent prior to enrollment.

Participant smoking history, cpd, and measures of nicotine dependence, withdrawal, and craving were assessed weekly for the first 4 weeks and at the 12th week using the Fagerström Test for Nicotine Addiction (FTND) (Heatherton et al., [@B23]), Minnesota Nicotine Withdrawal Scale (M-NWS; 7 items following DSM-IV criteria for nicotine withdrawal) (Hughes and Hatsukami, [@B25]), and the Questionnaire of Smoking Urges Short Form (QSU-brief; 10 item measure of craving) (Cox et al., [@B11]). Common side effects associated with the use of pharmacotherapy and quitting smoking were assessed using the Symptoms and Side Effects questionnaire (SSE; 30 items) (Markou, [@B33]). Depressive symptoms were assessed using the Center for Epidemiological Studies on Depression Scale (CES-D; 20 item self-report measuring depression) (Radloff, [@B42]), and the Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ) (Torrubia et al., [@B52]) was administered to determine the valence of external rewards and punishments. Expired air carbon monoxide (CO) concentration in parts per million was measured by a Vitalograph BreathCO monitor (Vitalograph, Inc., Lenxa, KS) once a week for the first 4 weeks as well as prior to the second scan and used in combination with participant cpd self-report to confirm smoking status. Smokers were allowed to smoke up to 1 h before the scanning session to avoid nicotine intoxication or withdrawal.

Study design and pharmacological intervention
---------------------------------------------

Participants were scanned at baseline and after 12 weeks of treatment with varenicline. Following the first scan, participants completed 4 weekly sessions of a modified version of the individual-based Tobacco Dependence Treatment Program (ACT) (Payne and Crews, [@B41]) and were given daily manufacturer-recommended dosing of varenicline (Pfizer Global Pharmaceuticals, New York, NY). Dosing schedule consisted of 0.5 mg for the first 3 days, 0.5 mg twice daily for the next 4 days, and 1.0 mg twice daily for the next 12 weeks. Nine participants dropped out after the first scanning session, and two participants dropped out after the first ACT session. Two of the participants who dropped out were excluded from baseline fMRI analyses due to missing behavioral responses during the task, and one revoked consent. Eleven participants remained in the study completing all four ACT sessions. Participant compliance was checked using pill counting on a weekly basis. These 11 participants were scanned within 1 week following the completion of the varenicline regimen.

Imaging parameters
------------------

All imaging was performed on a 3T single channel transmit receive head-only Siemens Magnetom Allegra scanner. fMRI data were acquired using a gradient recalled echo-planar imaging (EPI) sequence (repetition time/echo time \[*TR*/*TE*\] = 2100/30 ms, flip angle = 70°, field of view = 24 × 24 cm^2^, 64 × 64 matrix, 4-mm slice thickness, 1-mm gap, 26 axial slices). A three-dimensional T1-weighted magnetization prepared rapid acquisition gradient-echo sequence (MP-RAGE) structural scan with 1-mm isotropic voxels was acquired for anatomical reference (*TR*/*TE*/*TI* = 2300/3.93/1100 ms, flip angle = 12°, 256 × 256 matrix).

### ^1^H-MRS

A ^1^H-MRS voxel was placed in the bilateral dACC as described previously (Reid et al., [@B44]). Manual shimming was performed to optimize field homogeneity across the voxel, and chemical shift selective pulses were used to suppress the water signal. Spectra were acquired using the point-resolved spectroscopy sequence (PRESS; *TR*/*TE* = 2000/80 ms to optimize the glutamate signal and minimize macromolecule contribution, number of averages = 256, scanning time = 8 min 32 s; voxel size 2.7 × 2 × 1 cm^3^) (Bottomley, [@B7]). MRS data were analyzed in jMRUI (version 3.0) (see Methods in Reid et al., [@B44]). Briefly, the model consisted of peaks for *N*-acetyl aspartate (NAA), choline (Cho), creatine (Cr), and three peaks for glutamate + glutamine (Glx). NAA, Glx, and Cho were quantified with respect to Cr. Only Glx peaks are reported and discussed in this study. The MRS voxel was positioned on an individual basis at baseline and week 12 to maximize gray matter based on cortical landmarks. Of the participants who did complete the study, one participant did not have post-varenicline MRS spectra, leaving 10 study completers with MRS spectra pre- and post-varenicline.

### fMRI

An IFIS-SA system running E-Prime software (1.2; Psychology Software Tools, Pittsburgh, Pennsylvania) was used to control stimulus delivery and to record button press responses and reaction times. Participants performed a version of the Stroop color-naming task as described previously (Reid et al., [@B44]). Stimuli were three words, "RED," "GREEN," or "BLUE," printed in one of those three colors. Incongruent trials were those in which the word and color were different. Participants were instructed to indicate the color of the word and ignore the meaning of the word. The experiment consisted of three runs of 88 trials. The 3 second trials comprised a word stimulus for 1.5 seconds and a fixation cross for 1.5 seconds. fMRI data analyses were implemented in SPM8 (Wellcome Trust Centre for Neuroimaging). Preprocessing of the fMRI data included slice timing correction, motion correction using ArtRepair (0.5 mm cutoff; CIBSR Stanford University, CA), reslicing to 2-mm isotropic voxels, coregistration to the baseline structural scan, smoothing with a 4 mm full width at half maximum Gaussian kernel, and DARTEL normalization to a group template brain and then standard Montreal Neurological Institute space to facilitate between-subjects comparison (Ashburner, [@B3]). No subjects were excluded based on movement.

Statistical analyses
--------------------

### Behavior

All behavioral scales and responses were analyzed in PASW Statistics 18 (IBM SPSS Inc., Chicago, IL). Comparisons between groups on smoking and other behavioral measures were done using chi-square and analysis of variance (ANOVA) procedures, as appropriate. Paired *t*-tests were used to examine change across the two time points. The Stroop effect was defined as mean reaction time during congruent trials subtracted from mean reaction time during incongruent trials.

### MRS

Independent samples *t*-tests were used to assess Glx/Cr at baseline between study completers and study non-completers. A paired samples *t*-test was used to assess the change in Glx/Cr from baseline to week 12 in study completers.

### fMRI

Statistical tests involved two levels, the single-subject level (fixed effects) and the group level (random effects). At the first level, statistical analyses of fMRI data consisted of a single-subject voxel-by-voxel general linear model. Five conditions were included in the model including incongruent trials, congruent trials, error trials, no response trials, and stimulus repetitions (defined as any trial that was an exact repetition of the previous trial) (Reid et al., [@B44]). Conditions were convolved with the canonical hemodynamic response function with a temporal derivative. Statistical parametric maps (SPMs) were generated for the contrast of correct incongruent trials minus correct congruent trials (Stroop effect). These contrasts were then used at the second level. One sample *t*-tests were used to assess the group mean differences in the Stroop effect at baseline and after treatment with varenicline. A paired samples *t*-test was used to make comparisons between the two time points. Additionally, CO was added to analyses at the second level as a covariate of no interest to account for differential effects of nicotine. Results were not substantially altered by adding this covariate. All images were set at a statistical significance threshold of *p* \< 0.05 with family-wise error (FWE) cluster-level correction. To assess the possibility of type II error due to the small sample size, effect size (Cohen\'s *d*) was calculated voxel-wise for the paired samples comparisons of fMRI data.

### Psychophysiological interaction (PPI)

Modulatory interactions using a dACC seed region were assessed using the PPI toolbox in SPM8 (Friston et al., [@B18]). The PPI analysis consists of a design matrix with three regressors: the "psychological variable" in this case the Stroop effect (correct incongruent trials---correct congruent trials), the "physiological variable" representing the signal time course in the seed region (anterior dACC), and a variable representing the interaction of the two previous terms---the psychophysiological interaction. The anterior dACC was defined as one slice forward from the disappearance of the juncture of the anterior corpus callosum from both hemispheres and the posterior end as the first vertical slice posterior to the anterior commissure. Using this structurally defined region of interest (ROI), a time series from the anterior dACC was extracted from each participant\'s contrast for the Stroop Effect condition. SPMs were thresholded at *p* \< 0.05 to ensure the presence of BOLD signal in all participants. A variable representing the interaction term between each time series and the psychological variable (Stroop effect) was constructed for each participant. Subject-specific contrast images representing functional connectivity of the anterior dACC during Stroop were then entered into a paired samples *t*-test in order to assess differences in connectivity between baseline (pre-varenicline) and week 12 (post varenicline) (see **Figure 2**, **Table 4**). FWE cluster-level correction (*p* \< 0.05) was applied to all group-level contrasts.

### Exploratory analyses

Pearson\'s correlations were used to assess the relationship between dACC Glx and smoking related measures including nicotine dependence (FTND) and nicotine craving (QSU-sf). Bonferroni correction was applied to all correlations.

### Study completers vs. study non-completers

We compared study completers and those who dropped out after the baseline scan on baseline characteristics, Glx and BOLD response. *T*-tests were performed to assess differences on smoking parameters and dACC Glx. BOLD differences were assessed during the Stroop effect at baseline using SPM8 (*p* \< 0.05 FWE cluster level corrected).

Results {#s3}
=======

Seven of the 11 study completers (64%) stopped smoking entirely with the other four participants significantly decreasing their cigarette consumption \[pre-varenicline cpd *M* = 27.50, *SD* = 15.00 to post-varenicline cpd *M* = 5.50, *SD* = 6.40, *t*~(3)~ = 3.26, *p* = 0.047\]. Study completers had significantly lower craving (QSU-sf) scores at week 12. Symptoms of withdrawal (MNWS), sensitivity to reward (SPSRQ), depression (CESD), and symptoms (SSE) did not significantly change pre- to post-varenicline treatment (Table [1](#T1){ref-type="table"}).

###### 

**Study Completers: Behavioral and Clinical Measures**.

  **Characteristic**                                         **Baseline (Pre-drug)**   **Week 12 (Post-drug)**   ***t*-value**   ***p*-value**
  ---------------------------------------------------------- ------------------------- ------------------------- --------------- ---------------
  **SMOKING BEHAVIOR**                                                                                                           
  CO[^\*^](#TN1){ref-type="table-fn"}                        19.27 ± 8.48              4.36 ± 5.70               6.71            \<0.001
  CPD                                                        23.60 ± 9.20              2 ± 4.4                   9.01            \<0.001
  **STROOP TASK BEHAVIOR**                                                                                                       
  Congruent RT                                               799 ± 14                  762 ± 9                   2.36            0.04
  Incongruent RT                                             956 ± 17                  918 ± 13                  1.73            0.12
  Stroop effect RT                                           154 ± 8                   158 ± 6                   −0.29           0.78
  Task errors                                                4.36 ± 2.94               11.27 ± 18.00             −1.24           0.24
  **CLINICAL MEASURES[^\*\*^](#TN2){ref-type="table-fn"}**                                                                       
  FTND                                                       5.89 ± 2.0                --                        --              --
  MNWS                                                       9.22 ± 5.61               6.00 ± 6.67               1.04            0.33
  QSU-brief                                                  39.11 ± 15.37             11.89 ± 3.52              4.54            0.002
  SPSRQ                                                      14.44 ± 5.92              16.44 ± 7.59              −1.73           0.12
  CESD                                                       9.67 ± 4.24               9.33 ± 4.64               0.23            0.83
  SSE                                                        45.44 ± 12.07             38.67 ± 8.02              1.64            0.14

*CESD, Center for Epidemiological Studies on Depression; CO, carbon monoxide; CPD, cigarettes per day; FTND, Fagerström Test for Nicotine Addiction; MNWS, Minnesota Nicotine Withdrawal Scale (Hughes-Hatsukami Withdrawal Scale); RT, reaction time in milliseconds; SPSRQ, Sensitivity to Punishment and Sensitivity to Reward Questionnaire; SSE, Symptoms and Side Effects; QSU-brief Questionnaire of Smoking Urges Short Form*.

*FTND week 12 scores have been omitted. Two of the seven items on the FTND are related to recent smoking behavior. Because subjects are enrolled in a study to reduce smoking behavior, reduced scores on this measure may reflect behavioral changes and not nicotine dependence per se*.

*scores imputed for two participants*.

*scores missing for two participants*.

Behavioral
----------

There were no significant changes in Stroop effect reaction time nor differences in number of errors pre-to-post varenicline. Reaction time on congruent trials was significantly faster at the post-varenicline scan (Table [1](#T1){ref-type="table"}).

MRS
---

Study completers had significantly higher Glx/Cr pre-varenicline than post-varenicline (see Table [2](#T2){ref-type="table"}, Figures [1A,B](#F1){ref-type="fig"}). Cr did not significantly differ pre- to post-varenicline *t*~(9)~ = −0.889, *p* = 0.397.

###### 

**Glutamate Measurement in Dorsal Anterior Cingulate Cortex**.

  **Metabolite**   **Baseline completers**   **Week 12 completers**   ***t*-value**   ***p*-value**
  ---------------- ------------------------- ------------------------ --------------- ---------------
  Glx/Cr           0.705 ± 0.089             0.646 ± 0.045            2.743           0.023
  CRLB ± *SD*      7.1 ± 1.7%                6.9 ± 1.5%                               
  (CRLB Range)     (5.8--11.6%)              (5.4--10.2%)                             

*Cr, creatine; CRLB, Cramer-Rao Lower Bounds; Glx, glutamate + glutamine*.

*There were no significant differences in the raw amplitude of Cr between baseline (pre-drug) and week 12 (post-drug) t~(9)~ = −0.889, p = 0.397. There were no significant differences between baseline to week 12 in metabolite peak line width, CRLBs, gray matter voxel content, or white matter voxel content*.

![**Dorsal anterior cingulate (dACC), glutamate + glutamine (Glx)/creatine (Cr), baseline (pre-drug), and at week 12 (post-drug) for study completers. (A)** Box plot of median Glx/Cr in the dACC at baseline and week 12. **(B)** Line plot of individual Glx/Cr in the dACC at baseline and week 12. Asterisk indicates significant *t*-statistic at *p* \< 0.05.](fphar-05-00158-g0001){#F1}

fMRI
----

Within-group at baseline and week 12 *t*-tests as well as between baseline and week 12 paired *t*-tests of the BOLD during the Stroop Effect are presented in **Figures 2A--C**. Regions including the anterior cingulate, bilateral anterior insula/frontal operculum, right supramarginal/angular gyri, and bilateral dorsolateral prefrontal cortex were identified as significantly activated during incongruent-congruent contrasts in both pre- and post-varenicline scans (**Figures 2A,B**, Table [S1](#SM1){ref-type="supplementary-material"}). These regions are those typically activated with the Stroop task (Botvinick et al., [@B8]) and are consistent with activation of the CCN (Niendam et al., [@B38]). In post-varenicline scans, a significant deactivation can be seen in the rostral ACC extending into the medial orbitofrontal cortex (mOFC), as well as deactivation in the middle cingulate, precuneus, and left temporal lobe (Figure [2B](#F2){ref-type="fig"}). Deactivation in the post-varenicline scan drove the significant decreased activation in the rostral ACC/mOFC and precuneus seen in the post \> pre-varenicline contrast (Figure [2C](#F2){ref-type="fig"}, Table [3](#T3){ref-type="table"}). No regions survived cluster level correction in week 12 \> baseline contrasts. Effect size calculation for contrast of post \> pre-varenicline showed medium to large effect size across many areas of the brain (Figure [S1](#SM1){ref-type="supplementary-material"}).

![**Stroop task BOLD contrasts and Psychophysiological Interaction (PPI) analysis results**. Group BOLD activation (red) and deactivation (blue) maps shown for BOLD at baseline scans pre-drug **(A)**, BOLD for week 12 scan post-drug **(B)**, and BOLD Post\>Pre-drug **(C)** as well as PPI for baseline scan pre-drug **(D)**, PPI post-drug **(E)**, and PPI Post\>Pre-drug **(F)**. All color intensities are voxel-wise *t*-statistics with significance *p* \< 0.05 FWE cluster-level correction. Activation maps are overlaid onto the averaged anatomical scan Colin27 in MRIcron and are displayed in neurological view (left is on the viewer\'s left). (1) Supplementary Motor Area (SMA); (2) Inferior Frontal Gyrus; (3) Insula; (4) Middle Temporal Gyrus; (5) rostral ACC connected to medial orbitofrontal cortex; (6) Posterior Cingulate; (7) Inferior Parietal; (8) Thalamus.](fphar-05-00158-g0002){#F2}

###### 

**Areas with Significant Changes in BOLD Signal for the contrast incongruent greater than congruent following smoking cessation therapy with varenicline**.

  **Region**                **Hem**   ***x*, *y*, *z***   **Cluster size**   **peak *t*-Value**
  ------------------------- --------- ------------------- ------------------ --------------------
  **BASELINE\>WEEK 12**                                                      
  Anterior cingulum         L         −5, 48, 0           840                7.76
  **Cluster sub regions**                                                    
  Anterior cingulum         R                             404                
  Middle cingulum           R                             229                
  Precuneus                 R                             430                
  Caudate                   L                             203                
  Superior frontal          R                             159                
  Medial sup frontal        L, R                          819, 279           
  Medial OFC                L, R                          324, 152           
  Middle temporal           L         −50, −41, 12        339                6.51

*Hem, hemisphere; OFC, Orbitofrontal Cortex; SMA, Supplementary Motor Area; x, y, z refers to Montreal Neurological Institute coordinates. All regions are significant at a cluster level threshold of p \< 0.05 FWE cluster level corrected. No regions survived thresholding in Week 12 \> Baseline contrast. See Table [S1](#SM1){ref-type="supplementary-material"} for within group results*.

PPI
---

Voxelwise PPI connectivity with the dACC seed region is presented in Figure [2D](#F2){ref-type="fig"}. At baseline and week 12, only regions negatively correlated with the dACC seed region survived statistical thresholding (Figures [2D,E](#F2){ref-type="fig"}). Regions including bilateral superior medial frontal, rostral ACC, precuneus, middle, and posterior cingulate were significantly negatively correlated with the dACC seed region at baseline (Figure [2D](#F2){ref-type="fig"}). At week 12, dACC was negatively correlated with sensory motor area, bilateral inferior, and superior parietal lobe, precuneus, middle occipital lobe, thalamus, and temporal gyrus (Figure [2E](#F2){ref-type="fig"}, Table [S2](#SM1){ref-type="supplementary-material"}). Bilateral medial superior frontal, bilateral rostral ACC, as well as, bilateral posterior and middle cingulum, and bilateral precuneus were significantly more negatively correlated at baseline than at week 12 (Figure [2F](#F2){ref-type="fig"}, red). Bilateral inferior parietal and right superior occipital were significantly more negatively correlated at week 12 than baseline (Figure [2F](#F2){ref-type="fig"} blue, Table [4](#T4){ref-type="table"}).

###### 

**Changes in dACC functional connectivity for the contrast incongruent greater than congruent following smoking cessation therapy with varenicline**.

  **Region**                **Hem**   ***x*, *y*, *z***   **Cluster size**   **peak *t*-Value**
  ------------------------- --------- ------------------- ------------------ --------------------
  **BASELINE\>WEEK 12**                                                      
  Inferior parietal         R         36, −47, 45         655                7.69
  SupraMarginal gyrus       R                             279                
  Superior occipital        R         33, −72, 42         300                6.37
  Angular gyrus             R                             252                
  Superior parietal         R                             237                
  Inferior parietal         L         −18, −72, 45        549                5.41
  Superior parietal         L                             403                
  **WEEK 12 \> BASELINE**                                                    
  Superior medial frontal   R         17, 48, 5           389                7.88
  Anterior cingulum         R, L                          202, 134           
  Superior frontal          R                             190                
  Superior medial frontal   L                             124                
  Superior orbitofrontal    R                             110                
  Posterior cingulum        L         −8, −24, 29         245                5.73
  Middle cingulum           L                             245                
  Precuneus                 R, L                          175, 170           
  Posterior cingulum        R                             117                

*Hem, hemisphere; x, y, z refer to Montreal Neurological Institute coordinates. All regions are significant at a cluster level threshold of p \< 0.05 FWE cluster level corrected*.

Exploratory analyses
--------------------

A positive correlation was found between baseline nicotine dependence (FTND) and baseline Glx/Cr (Figure [3A](#F3){ref-type="fig"}) as well as between baseline nicotine craving (QSU-sf) and baseline Glx/Cr (Figure [3B](#F3){ref-type="fig"}). At baseline, degree of nicotine dependence (Figure [3B](#F3){ref-type="fig"}) and nicotine craving (Figure [3B](#F3){ref-type="fig"}) positively correlates with amount of Glx/Cr in the dorsal cingulate. Due to the small sample size and inherent floor effects of the FTND and QSU-sf, post-varenicline nicotine dependence and nicotine craving did not correlate with post-varenicline Glx/Cr.

![**Baseline scales of nicotine dependence (FTND) and nicotine craving (QSU-sf) correlate with baseline dACC Glx/Cr. (A)** Correlation of Fagerström Test for Nicotine Addiction (FTND) and Glx/Cr: *R*^2^ = 0.558, Pearson *r* = 0.747, *p* = 0.002 two-tailed, significant after Bonferroni Correction **(B)** Questionnaire of Smoking Urges Short Form (QSU-sf), *R*^2^ = 0.458, Pearson *r* = 0.677, *p* = 0.008 two-tailed, significant after Bonferroni Correction. Two completers and five non-completers are missing FTND and QSU-sf data, and one non-completer is missing Glx, leaving a baseline group of 13 participants. FTND and QSU-sf scores were not significantly correlated *r* = 0.378 *p* = 0.165.](fphar-05-00158-g0003){#F3}

Study completers vs. study non-completers
-----------------------------------------

There were no significant differences between study completers and those who dropped out after the baseline scan on demographics, Stroop effect, smoking behavior, history, or clinical scales (Table [5](#T5){ref-type="table"}). Baseline Glx/Cr was not significantly different between study non-completers (*n* = 11) and study completers (*n* = 10) *t*~(19)~ = 0.217, *p* \> 0.05 (Table [S4](#SM1){ref-type="supplementary-material"}). Subcortical regions including the striatum and thalamus, as well as, cortical regions including bilateral insula, left temporal gyrus, and left middle and inferior frontal gyri were significantly more active at baseline in study non-completers than in study completers (Figure [4](#F4){ref-type="fig"}, Table [S3](#SM1){ref-type="supplementary-material"}).

###### 

**Baseline Characteristics of Study Participants**.

                                                        **Both groups (***n*** = **22**)**   **Study completers (***n*** = **11**)**   **Study non-completers (***n*** = **11**)**   ****t**/χ^2^**   ***p*-value**
  ----------------------------------------------------- ------------------------------------ ----------------------------------------- --------------------------------------------- ---------------- ---------------
  **DEMOGRAPHICS**                                                                                                                                                                                    
  Gender M, F                                           10/12                                4/7                                       6/5                                           0.73             0.39
  Race C, AA                                            17/5                                 8/3                                       9/2                                           0.23             0.61
  Age                                                   36.32 ± 11.86                        36.0 ± 11.19                              36.64 ± 13.03                                 −0.12            0.90
  Education[^a^](#TN3){ref-type="table-fn"}             2.91 ± 0.68                          3.09 ± 0.54                               2.73 ± 0.79                                   1.27             0.22
  Parental occupation[^b^](#TN4){ref-type="table-fn"}   7.36 ± 5.02                          6.0 ± 3.92                                8.73 ± 5.78                                   −1.30            0.21
  **SMOKING BEHAVIOR**                                                                                                                                                                                
  CO[^\*^](#TN7){ref-type="table-fn"}                   18.87 ± 9.05                         19.27 ± 8.48                              17.75 ± 11.84                                 0.28             0.79
  CPD                                                   24.60 ± 8.60                         23.60 ± 9.20                              25.40 ± 8.20                                  −0.49            0.63
  **SMOKING HISTORY[^c^](#TN5){ref-type="table-fn"}**                                                                                                                                                 
  Years of smoking                                      22.46 ± 14.09                        18.06 ± 12.67                             28.33 ± 14.80                                 −1.40            0.19
  Age daily smoker                                      17.36 ± 2.74                         17.88 ± 2.53                              16.67 ± 3.08                                  0.81             0.44
  Prior quit attempts                                   3.71 ± 3.83                          4.88 ± 3.56                               2.17 ± 3.92                                   1.35             0.20
  **SMOKING SCALES[^d^](#TN6){ref-type="table-fn"}**                                                                                                                                                  
  FTND                                                  5.80 ± 2.27                          5.89 ± 2.21                               5.67 ± 2.58                                   0.18             0.86
  M-NWS                                                 9.87 ± 6.63                          9.22 ± 5.61                               10.83 ± 8.42                                  −0.45            0.66
  QSU-brief                                             33.93 ± 19.19                        39.11 ± 15.37                             26.17 ± 23.06                                 1.31             0.21
  SPSRQ                                                 14.94 ± 8.28                         16.70 ± 9.06                              12.0 ± 6.45                                   1.11             0.29
  CESD                                                  9.67 ± 4.69                          9.67 ± 4.24                               9.67 ± 5.72                                   0.00             1.00
  SSE                                                   40.07 ± 15.60                        45.44 ± 12.07                             32.0 ± 17.84                                  1.75             0.10

*AA, African American; C, Caucasian; CESD, Center for Epidemiological Studies on Depression; CO, carbon monoxide; CPD, cigarettes per day; F, Female; FTND, Fagerström Test for Nicotine Addiction; M, Male; M-NWS, Minnesota Nicotine Withdrawal Scale (Hughes-Hatsukami Withdrawal Scale); SPSRQ, Sensitivity to Punishment and Sensitivity to Reward Questionnaire; SSE, Symptoms and Side Effects; QSU-brief, Questionnaire of Smoking Urges Short Form*.

*Education was scored on a scale from 1 to 4; (1) completed kindergarten through 8th grade; (2) 9th grade through highschool graduate; (3) some college through college graduate; (4) postgraduate education*.

*Ranks determined from the Diagnostic Interview for Genetic Studies (1--18 scale); higher rank (lower numerical value) corresponds to higher socioeconomic status*.

*Baseline scores are missing for nine participants*.

*Responses are missing for seven participants*.

*Scores imputed for seven study completers and two study non-completers*.

![**Baseline BOLD for Study Completers vs. Study Non-completers**. All color intensities are voxel-wise *t*-statistic, *p* \< 0.05 FWE cluster-level corrected. Other conventions as in Figure [1](#F1){ref-type="fig"}. (1) Putamen; (2) Insula.](fphar-05-00158-g0004){#F4}

Discussion {#s4}
==========

The aim of this study was to evaluate the effects of 12 week varenicline administration on Glx/Cr in the dorsal ACC (dACC) and functional changes within the CCN. Following treatment we observed a significant decrease in dACC Glx/Cr levels, as well as, significant BOLD decreases in the rostral ACC (rACC)/mOFC and precuneus/posterior cingulate cortex (PCC). These BOLD changes are suggestive of alterations in DMN function, and are further supported by the results of the PPI analysis that revealed changes in FC between the dACC and regions of the DMN. Baseline measures of nicotine dependence and craving positively correlated with baseline Glx/Cr levels. Finally, at baseline, study non-completers had significantly more task activation in the ventral striatum, thalamus, and insular cortex than study completers.

To our knowledge there have been no previous MRS studies of pharmacologically supported smoking cessation. As hypothesized, we observed a significant decrease in dACC Glx/Cr levels after treatment (Figure [1A](#F1){ref-type="fig"}). This 8.7% Glx decrease is in the range of that observed with the use of memantine, an N-methyl-D-aspartate (NMDA) antagonist used for the treatment of Alzheimer\'s disease (van Wageningen et al., [@B54]). In a group of active smokers, Gallinat and colleagues found that dACC Glx levels were not significantly different than those of non-smokers or former smokers (Gallinat and Schubert, [@B19]). These data suggest the Glx decrease seen in this study cannot be interpreted as normalizing Glx levels from an increased state and point toward a drug effect. These results concur with preclinical research showing that reducing glutamatergic transmission through pharmacological manipulations decreases the rewarding effect of nicotine (Markou, [@B33]) and suggest a mechanism by which varenicline improves abstinence.

To investigate the relationship between glutamate and nicotine addiction we correlated a measure of baseline nicotine dependence (FTND total score) and baseline craving (QSU-sf) with baseline Glx/Cr. Both nicotine dependence and craving were significantly and positively correlated with Glx levels (Figures [3A,B](#F3){ref-type="fig"}). Interestingly, positive correlations between craving and rostral ACC Glx levels in alcohol-dependent patients immediately after detoxification (Bauer et al., [@B5]) and between impulsivity and dorsal ACC Glx (Hoerst et al., [@B24a]) have been reported. Collectively, these data suggest a role for ACC glutamate in the modulation of behavior. In addition, thalamic Glx/Cr was found to be higher in patients suffering from restless legs syndrome (RLS) (Allen et al., [@B1]), and case report found RLS amelioration with varenicline treatment (Romigi and Vitrani, [@B46]), suggesting a potential mechanism whereby varenicline may reduce thalamic Glx levels in these patients.

After treatment, we observed significant BOLD decreases in rACC/mOFC and precuneus/PCC (Figure [2C](#F2){ref-type="fig"}). These results show similarities to previous imaging studies with varenicline. After 3 days of nicotine abstinence, while on varenicline, working memory-related brain activity was increased, especially at higher task difficulty, and was associated with improved cognitive performance (Loughead et al., [@B31]). Interestingly, a whole-brain analysis of this study revealed enhanced deactivations of PCC and rACC in association with varenicline. In non-abstinent smokers, 3 weeks of varenicline administration resulted in a decreased response to smoking cues in the ventral striatum and mOFC (Franklin et al., [@B17]). Further, abstinent smokers and non-smokers demonstrated decreased resting state DMN connectivity with the insula after 17 days of varenicline (Sutherland et al., [@B49]). Thus, similar to our results, these studies found alterations in regions of the DMN in association with smoking cessation with varenicline. In this study, these alterations were observed in the face of unchanged task performance.

We evaluated changes in FC during task performance using PPI analysis. Prior to treatment, there was a significant negative FC between the dACC seed and the rACC and PCC, both regions of the DMN (Figure [2D](#F2){ref-type="fig"}). Activities in the CCN and the DMN have been shown to be negatively related (Fox et al., [@B16]) so that during task performance the DMN is deactivated in proportion to CCN activation. The loss of this negative coupling appears to interfere with proper task performance (Sonuga-Barke and Castellanos, [@B48]) while greater negative coupling is usually regarded as advantageous in allocating cognitive resources during task (Kelly et al., [@B28]). Our pre-varenicline results replicate previous findings of negative functional coupling between the CCN and DMN regions.

Recent studies have reported greater deactivation of the DMN with acute nicotine administration that was associated with improved task performance (Hahn et al., [@B21]; Ettinger et al., [@B14]). Furthermore, during resting state fMRI, acute nicotine administered to abstinent smokers increased the negative FC between CCN and DMN networks, an effect associated with improvement in withdrawal symptoms (Cole et al., [@B10]). In this study, after varenicline, the negative FC between the CCN seed and the DMN was reduced while there was an increased negative FC between the seed and the bilateral inferior parietal cortex (Figure [2F](#F2){ref-type="fig"}). Increased connectivity between a dACC seed region and parieto-occipital cortex has been found to distinguish cannabis users from controls in an emotional color word Stroop (Harding et al., [@B22]). The parieto-occipital attention network plays a role in selecting relevant objects and directing appropriate behaviors (Hopfinger et al., [@B24]). The role of the dACC has been ascribed to direct attention based on behaviorally relevant stimuli (Weissman et al., [@B55]). Thus, increased negative FC between dACC and regions of the fronto-parietal network may suggest changes in attentional bias toward drug related stimuli. In contrast to studies of the acute effects of nicotine on the DMN (Hahn et al., [@B21]; Ettinger et al., [@B14]), the changes in FC reported here were observed after treatment, at a time when participants did not experience symptoms of withdrawal or craving, and most of them had stopped smoking. Based on these observations, we have hypothesized that changes in brain network dynamics are key to understanding the mechanism of sustained action of antismoking drugs.

Nicotine addiction has been linked to its ability to release dopamine through activation of α4β2 nAChRs located on pre-synaptic neurons of the mesolimbic dopamine system (Benowitz, [@B6]). Smoking-induced increase in dopamine release produces changes in synaptic plasticity (Kalivas and O\'Brien, [@B27]) that reinforce smoking behavior (Fiore et al., [@B15]) a process leading to addiction. Thus, it is possible varenicline affects the rACC and mOFC through its action on mesolimbic dopaminergic neurons. Speculatively, BOLD changes in these regions could trigger concomitant changes in other regions of the DMN, including the PCC.

While Mashhoon et al. ([@B34]) found that higher Glx/Cr in smokers predicted those who would relapse into smoking, we did not find that Glx/Cr differentiated study completers and non-completers. Perhaps one of the more interesting findings from this study is that treatment completers and non-completers did not differ in demographic and clinical characteristics, but did differ in that non-completers had increased baseline fMRI BOLD intensities in the putamen and insula (Figure [4](#F4){ref-type="fig"}). Such a finding could be an important clue for future work to help clarify the neurobiological substrates of treatment failure in smoking cessation, especially since these findings appear to be better predictors than any clinical or demographic information available. Converging evidence links the ventral striatum to reward processing (Koob and Volkow, [@B30]), our results point toward differences in activation of the reward system between the two groups. The role of the insula has been linked to the monitoring of internal bodily states and to the processing of subjective feelings (Craig, [@B12], [@B13]). The insula and connected networks appear to play a critical role in addiction, including nicotine addiction (Naqvi et al., [@B37]; Sutherland et al., [@B50]). Importantly, damage to the insula, such as in stroke, can disrupt nicotine addiction (Naqvi et al., [@B37]). In addition, activity in the insula correlates with cue-induced drug urges (Brody et al., [@B9]).

Our study has several limitations. The study was not placebo controlled, and the design did not allow disentangling the effects of smoking cessation and varenicline. This study design also did not allow an assessment of potential practice effects due to participants completing the Stroop again, 12 weeks later. Because cerebral blood flow (CBF) can influence the BOLD signal (Kim and Ogawa, [@B29]), and because varenicline alters CBF (Franklin et al., [@B17]), it is possible that the observed changes in BOLD activation and connectivity were influenced by changes in CBF. While this study controlled for false positive rates in the fMRI results with FWE correction, the small sample size may lead to false negatives. Furthermore, the results should be considered as preliminary given the small sample size, the number of dropouts, and single-arm open label design of the study. Therefore, these fMRI findings should be confirmed in additional studies in a larger sample with a double blind randomized control trial with smokers and non-smokers. Further studies are needed to understand the relationship of varenicline to glutamate and brain networks dynamics. The quantification of glutamate with ^1^H-MRS is difficult. Glutamate, glutamine (the major metabolite of synaptic glutamate), and GABA have overlapping peaks that are difficult to resolve at low magnetic field strength. A single peak termed Glx containing the three peaks is usually reported. The Glx peak cannot be simply equated with glutamatrgic neurotransmission as extracellular and vesicular glutamate represents only a small fraction of total brain glutamate. A technical strength of our study that partially compensates for this is the use of an echo time of 80 ms which appears to optimize the glutamate signal by diminishing macromolecule contribution and reducing glutamine contribution to the spectra (Bottomley, [@B7]; Schubert et al., [@B47]). Finally, the comparisons between completers vs. non-completers were based on small groups.

In conclusion, the results of this study suggest two possible mechanisms of action for varenicline: reduction in glutamate levels in ACC and shifts in BOLD activities between large scale brain networks. Understanding the mechanism of action of antismoking drugs is key to identifying novel and more efficacious compounds for smoking cessation. These findings are preliminary. Further studies are needed to assess the definitive mechanisms of varenicline.
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